



**Executive summary of
Cardiometabolic Pharmacist proposal Joint Working Agreement**

Published on [Working with the NHS \(astrazeneca.co.uk\)](http://Working with the NHS (astrazeneca.co.uk))

Project title	Cardiometabolic Pharmacist Joint Working Agreement
Duration	1 st September 2021 and ending on 31 st December 2022
Project partners	Medicines Optimisation and Innovation Centre (MOIC) at Northern Health & Social Care Trust (NHSCT) on behalf of the Western Health & Social Care Trust (WHSCT)
What was the issue to be addressed?	The overall objective of the project is to optimise the management of cardiometabolic patients with a specific focus on the prevention/delay to progression of cardiometabolic disease: 1) Identify patients early in the disease pathway who can benefit from early intervention to delay onset of cardiometabolic complications as a result of their diabetes and initiate therapy accordingly 2) Prevent development of or worsening Heart Failure in patients with/without diabetes by improving medicines optimisation in Heart Failure with a Reduced Ejection Fraction.
What were the results?	274 patients were reviewed by the pharmacist. 43% were invited to review clinic were initiated on SGLT2i therapy.

GB-47926 DOP: 18-08-2023